
RNTX Stock Forecast & Price Target
RNTX Analyst Ratings
Bulls say
Rein Therapeutics Inc is positioned favorably due to its focus on developing innovative therapies in the orphan pulmonary and fibrosis sectors, which exhibit substantial unmet medical needs. The company's leading candidates, LTI-03 and LTI-01, have demonstrated positive safety and efficacy indicators, with LTI-03 showing increased sRAGE levels in recipients, highlighting its potential impact in treating Idiopathic Pulmonary Fibrosis and loculated pleural effusion. Overall, the company's promising pipeline and potential for realizing a favorable risk-reward opportunity add to the optimism surrounding Rein Therapeutics's stock outlook.
Bears say
Rein Therapeutics Inc has experienced a significant decline in its stock performance, with shares down 50% year-to-date in 2025, substantially underperforming the XBI index's increase of 3.5%. This decline is primarily attributed to the company's decision to pause enrollments in U.S. clinical trials, leading to increased uncertainty regarding the progress of its clinical assets. Additionally, emerging data indicates that lower levels of soluble receptor for advanced glycation end-products (sRAGE) are associated with poor survival rates in patients with Idiopathic Pulmonary Fibrosis (IPF), further complicating the company's prospects in this therapeutic area.
This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNTX Analyst Forecast & Price Prediction
Start investing in RNTX
Order type
Buy in
Order amount
Est. shares
0 shares